Table 5 Diagnostic accuracy of the HITAS score in predicting the 90-day mortality of HBV–ACLF patients received glucocorticoid treatment.
Patients set | Cutoff points | No. | Survivors | Non-survivors | SE % (95% CI) | Sp % (95% CI) | PPV % (95% CI) | NPV % (95% CI) | PLR% (95% CI) | NLR% (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
Training cohort | 136 | 81 | 55 | |||||||
≤ 2.5 | 48 | 45 | 3 | |||||||
> 2.5 | 88 | 36 | 52 | 95 (85–99) | 56 (44–67) | 59 (48–70) | 94 (83–99) | 2.1 (1.7–2.6) | 0.1 (0.03–0.3) | |
≤ 3.47 | 91 | 74 | 17 | |||||||
> 3.47 | 45 | 7 | 38 | 69 (55–81) | 91 (83–97) | 84 (71–94) | 81 (72–89) | 8.0 (6.6–9.7) | 0.3 (0.2–0.8) | |
Validation cohort | 68 | 37 | 31 | |||||||
≤ 2.5 | 34 | 28 | 6 | |||||||
> 2.5 | 34 | 9 | 25 | 81 (63–93) | 76 (59–88) | 74 (55–87) | 82 (66–93) | 3.3 (2.6–4.3) | 0.3 (0.1–0.6) | |
≤ 3.47 | 41 | 31 | 10 | |||||||
> 3.47 | 27 | 6 | 21 | 68(49–83) | 84(71–95) | 78(60–93) | 76(61–88) | 5.0(3.8–6.6) | 0.4(0.1–1) |